These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22994779)

  • 21. A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients.
    Nishina T; Takano Y; Denda T; Yasui H; Takeda K; Ura T; Esaki T; Okuyama Y; Kondo K; Takahashi Y; Sugiyama Y; Muro K
    Jpn J Clin Oncol; 2013 Nov; 43(11):1080-6. PubMed ID: 23999770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln genes and prognosis of colorectal cancer in a Chinese population.
    Gan Y; Li XR; Chen DJ; Wu JH
    Asian Pac J Cancer Prev; 2012; 13(11):5721-4. PubMed ID: 23317245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer.
    Lv H; Han T; Shi X; Yao Y; Yao Y; Qiu W; Yue L; Liang J
    Med Oncol; 2014 Aug; 31(8):86. PubMed ID: 24958519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of ABCB-1, ERCC-1 and ERCC-2 gene polymorphisms on response to capecitabine and oxaliplatin (CAPOX) treatment in colorectal cancer (CRC) patients of South India.
    Varma A; Mathaiyan J; Shewade D; Dubashi B; Sunitha K
    J Clin Pharm Ther; 2020 Aug; 45(4):617-627. PubMed ID: 32399998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy.
    Li S; Zhu L; Yao L; Xia L; Pan L
    BMC Gastroenterol; 2014 Aug; 14():154. PubMed ID: 25175730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
    Yang Y; Xian L
    Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
    Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive Value of ERCC1, ERCC2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric Cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy.
    Yeh YS; Chen YT; Tsai HL; Huang CW; Ma CJ; Su WC; Huang CM; Huang MY; Hu HM; Lu CY; Wang JY
    Pathol Oncol Res; 2020 Apr; 26(2):1105-1116. PubMed ID: 31077069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
    Mo J; Luo M; Cui J; Zhou S
    Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
    Rumiato E; Cavallin F; Boldrin E; Cagol M; Alfieri R; Basso D; Castoro C; Ancona E; Amadori A; Ruol A; Saggioro D
    Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.
    Kjersem JB; Thomsen M; Guren T; Hamfjord J; Carlsson G; Gustavsson B; Ikdahl T; Indrebø G; Pfeiffer P; Lingjærde O; Tveit KM; Wettergren Y; Kure EH
    Pharmacogenomics J; 2016 Jun; 16(3):272-9. PubMed ID: 26261061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
    Kwon HC; Roh MS; Oh SY; Kim SH; Kim MC; Kim JS; Kim HJ
    Ann Oncol; 2007 Mar; 18(3):504-9. PubMed ID: 17322540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.
    Paré L; Marcuello E; Altés A; del Río E; Sedano L; Salazar J; Cortés A; Barnadas A; Baiget M
    Br J Cancer; 2008 Oct; 99(7):1050-5. PubMed ID: 18797464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.
    Kweekel DM; Gelderblom H; Antonini NF; Van der Straaten T; Nortier JW; Punt CJ; Guchelaar HJ
    Eur J Cancer; 2009 Mar; 45(4):572-8. PubMed ID: 19084393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.
    Chen YC; Tzeng CH; Chen PM; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
    Cancer Sci; 2010 Feb; 101(2):530-5. PubMed ID: 19922504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of ERCC1 C8092A and ERCC2 Lys751Gln polymorphisms with the risk of glioma: a meta-analysis.
    Xin Y; Hao S; Lu J; Wang Q; Zhang L
    PLoS One; 2014; 9(4):e95966. PubMed ID: 24763305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma.
    Puerta-García E; Urbano-Pérez D; Carrasco-Campos MI; Pérez-Ramírez C; Segura-Pérez A; Calleja-Hernández ; Cañadas-Garre M
    Surg Oncol; 2020 Dec; 35():388-398. PubMed ID: 33035787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.
    Cordova-Delgado M; Bravo ML; Cumsille E; Hill CN; Muñoz-Medel M; Pinto MP; Retamal IN; Lavanderos MA; Miquel JF; Rodriguez-Fernandez M; Liao Y; Li Z; Corvalán AH; Armisén R; Garrido M; Quiñones LA; Owen GI
    BMC Cancer; 2021 Sep; 21(1):1030. PubMed ID: 34525956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.